Effects of oxycodone for hysteroscopic surgery on EC50 and EC95 of propofol

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065606

Enrollment

Unknown

Registered

2022-11-09

Start date

2022-11-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

group 1:oxycodone 0.05mg/kg

group 2:oxycodone 0.1mg/kg

group 3:oxycodone 0.15mg/kg

group 4:oxycodone 0.2mg/kg

group 5:sufentanil 0.15ug/kg

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients undergoing hysteroscopic surgery under intravenous anesthesia.(ASA) Grade I-II, age 20-40, BMI 18-24. No electrolyte disorder, infection, immune and endocrine system diseases, no recent use of cardiovascular drugs, non-steroidal anti-inflammatory drugs, hormone drugs and anti-psychotic drugs.

Exclusion criteria

Exclusion criteria: Previous history of vaginal birth; Abnormal liver and kidney function; History of cardiopulmonary diseases; Sleep apnea syndrome; Long-term use of drugs such as diazepam; Long-term users of opioids; People allergic to oxycodone.

Design outcomes

Primary

Measure	Time frame
propofol EC50;	—

Secondary

Measure	Time frame
Intraoperative vital signs;The recovery time;	—

Countries

China

Contacts

Public ContactLili Xu

Women’s Hospital, Zhejiang University School of Medicine

xulili1202@126.com+86 18268144502

Outcome results